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Summary
Background: Tegoprazan is a novel, fast- and long- acting potassium- competitive acid 
blocker that suppresses gastric acid secretion, which could benefit patients with non- 
erosive reflux disease (NERD), a type of gastroesophageal reflux disease.
Aim: To evaluate the efficacy and safety profiles of tegoprazan compared with those 
of a placebo in Korean patients with NERD.
Methods: In this phase 3, double- blind, placebo- controlled, multicentre study, 324 Korean 
patients with NERD were randomised into three treatment groups: tegoprazan 50 mg, 
tegoprazan 100 mg and placebo. These drugs were provided once daily for 4 weeks. 
The primary endpoint was the proportion of patients with complete resolution of major 
symptoms (both heartburn and regurgitation) for the last 7 days of the 4- week treatment 
period. Other outcomes related to efficacy, safety and tolerability were also evaluated.
Results: Among all, 42.5% (45/106), 48.5% (48/99) and 24.2% (24/99) of patients 
showed complete resolution of major symptoms at week 4 after receiving tegoprazan 
50 mg, tegoprazan 100 mg, and placebo, respectively. Both doses of tegoprazan 
showed superior efficacy than the placebo (P = 0.0058 and P = 0.0004, respectively). 
The complete resolution rates of heartburn and proportions of heartburn- free days 
(as other efficacy outcomes) were significantly higher in both tegoprazan groups than 
in the placebo group (P < 0.05 for all). No significant difference in the incidence of 
treatment- emergent adverse events were noted.
Conclusions: Tegoprazan 50 and 100 mg showed superior therapeutic efficacy com-
pared with the placebo, as well as a favourable safety profile in patients with NERD.
Registration number: ClinicalTrials.gov identifier NCT02556021.
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1  | INTRODUC TION
About 4.4%- 14.0% of the adult population experience symptoms of 
gastroesophageal reflux disease (GERD), such as acid regurgitation 
and heartburn.1- 4 Among them, more than 50% exhibit normal oe-
sophageal mucosa on upper endoscopy, diagnosed as non- erosive 
reflux disorder (NERD).5- 8 NERD, which significantly compromises 
the patient quality of life (QoL), is commonly and daily seen in the 
clinical setting.5,6,8,9
Proton pump inhibitors (PPIs) are currently used as a first- line 
therapy for NERD,10,11 with the clinical goal of reducing reflux symp-
toms. However, previous studies showed that reflux symptoms were 
not completely resolved in approximately 30%- 55% of patients with 
NERD.12,13 Therefore, a new drug is needed to improve the clinical 
outcomes for patients with NERD.
Tegoprazan is a novel potassium- competitive acid blocker (P- 
CAB) that exhibits rapid and effective anti- secretory activity by re-
versibly binding to the H+/K+- ATPase on the parietal cell.13,14 P- CAB 
inhibits the proton pump through a competitive interaction with the 
potassium site of the enzyme without acid activation.14- 17 P- CAB 
blocks the active and the inactive forms of the proton pump. Thus, 
P- CAB inhibits the gastric acid secretion rapidly and for longer time, 
which could also improve the clinical outcomes, such as heartburn 
and regurgitation, in patients with NERD. Animal studies and clinical 
pharmacology studies in healthy volunteers demonstrated that tego-
prazan exhibited its maximum acid inhibitory effect rapidly and for 
a longer period than esomeprazole or revaprazan.18- 20 We assumed 
that these properties of tegoprazan would improve the clinical out-
comes, such as heartburn and regurgitation, in patients with NERD.
Therefore, in this study, we evaluated the efficacy— in terms of 
the proportion of patients with complete resolution of symptoms 
including heartburn and regurgitation (primary objective)— and the 
safety (secondary objective) of tegoprazan in patients with NERD 
compared with those of a placebo. The recommended clinical dose 
of tegoprazan was also determined.
2  | MATERIAL S AND METHODS
2.1 | Study subjects
Male or female patients were out- patients aged ≥20 years old who 
had recurrent typical GERD symptoms (heartburn and regurgitation) 
for ≥3 months before screening, both heartburn and regurgitation 
for 7 days prior to randomisation, and with mild severity for ≥2 days/
week or with moderate and severe ones for ≥1 day/week.
The major exclusion criteria included complications associated 
with erosive reflux disease (ERD), acute upper gastrointestinal bleed-
ing, acute gastritis, gastric or duodenal ulcer within 2 months before 
screening esophagogastroduodenoscopy (EGD), history of gastric 
or oesophageal surgery, Barrett's oesophagus or oesophageal stric-
ture, eosinophilic oesophagitis, Zollinger- Ellison syndrome, diagno-
sis of depression, abnormal laboratory test values at the screening 
(blood urea nitrogen and serum creatinine level, >1.5 upper limit of 
normal [ULN]; total bilirubin levels and serum levels of alanine ami-
notransferase, aspartate aminotransferase, alkaline phosphatase 
and gamma glutamyltransferase, >2 ULN) or any other conditions 
or diseases that an investigator considered not appropriate for this 
study. Pregnant and lactating female subjects were excluded from 
this study.
Patients were not allowed to concomitantly use any medica-
tions that could affect the efficacy evaluation, such as PPIs (within 
2 weeks before endoscopy), histamine receptor 2 blockers, prokinet-
ics or antacids (within 7 days before endoscopy), anti- depressants, 
anti- psychotics and anti- anxiety drugs.
2.2 | Study design and treatments
This was a phase 3, randomised, double- blind, multicentre (17 cen-
tres, 17 investigators in South Korea), placebo- controlled, parallel- 
group, three- arm study, conducted from September 2015 to 
November 2016. In this study, the therapeutic effect of tegoprazan 
50 and 100 mg, compared with that of the placebo, was analysed in 
patients with NERD who displayed normal mucosa at the screening 
EGD (endoscopic appearance of NERD defined as normal (N), ac-
cording to the Los Angeles classification). The clinical protocol was 
approved by the Institutional Review Boards of each institute and 
followed the Declaration of Helsinki and the International Congress 
on Harmonisation of Technical Requirements for Registration of 
Pharmaceuticals for Human Use— Good Clinical Practice (ICH- GCP) 
guidelines. The study was registered in ClinicalTrials.gov under the 
number NCT02556021. All patients signed the informed consent 
form before inclusion in the study and initiation of study procedures.
Following a screening period (2 weeks), patients were randomised 
1:1:1 (block randomisation, block size = 6) to receive orally and once 
daily either tegoprazan (50 or 100 mg) or placebo for 4 weeks. This 
study was assigned by central enrolment, and Interactive Web 
Response System (IWRS) was used for randomisation. All study 
drugs were manufactured by HK inno.N Corp. Patients with intol-
erable pain caused by NERD symptoms were allowed to take up to 
one dose per day of the rescue medication (Gelfos- M Suspension, 
Boryung Pharmaceutical Co., Ltd.).
Patients received tegoprazan 50 mg, 100 mg, or placebo, and 
rescue medication on day 1 and returned for visits at weeks 2, 4, 
and 6 (follow- up) for the assessment of NERD symptoms (Figure 1). 
Unused study drug and rescue medication were collected at weeks 
2 and 4, and new ones were dispensed at week 2. All study patients 
underwent a complete physical examination and were evaluated for 
treatment- emergent adverse events (TEAEs). Laboratory analyses 
and pregnancy tests for female patients were performed at screen-
ing, week 4, and follow- up visits.
Patient symptoms were assessed with the Reflux Disease 
Questionnaire (RDQ), in which patients were asked to report six 
symptoms covering three items (heartburn, regurgitation and dys-
pepsia) using a 12- item self- administered questionnaire, designed to 
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assess the frequency and severity of the symptoms. The mean RDQ 
score was calculated at baseline and at weeks 2 and 4 and follow- up 
visit. Heartburn and regurgitation were defined according to the 
Montreal definition. Heartburn was defined as a "burning sensation 
in the posterior bony thorax area (back of the bone, near the breast 
and in the epigastric region)"; meanwhile, regurgitation was defined 
as a "feeling of movement from the stomach to the mouth of the hy-
popharynx (the part adjacent to the oesophagus, below the airway), 
that resulted in a bitter or sour taste in the mouth."21
Patients recorded once a day the occurrence of heartburn and 
regurgitation without distinction of onset time (day or night time) 
in the patient diary (paper) before going to bed. The following 5- 
point scale, defined by the patient, assessed the severity of heart-
burn and regurgitation symptoms: no symptoms, mild: symptom did 
not interfere with routine activities including sleep; moderate: slight 
discomfort and interference with routine activities including sleep; 
severe: recurring symptoms that frequently interfered with routine 
activities including sleep; and very severe: consistent symptoms that 
substantially interfered with routine activities including sleep.
2.3 | Outcome measures
The primary efficacy endpoint was the proportion of patients with 
complete resolution of major symptoms (both heartburn and regur-
gitation) for the last 7 days of week 4 (treatment period), accord-
ing to the RDQ score.22,23 Complete resolution was defined as no 
symptoms. The secondary efficacy endpoints included RDQ- based 
complete resolution of the major symptoms at week 2, and of 
heartburn at weeks 2 and 4, and the proportions of days without 
heartburn during the 4- week treatment period, as reported in the 
patient's diary.
As patients with severe heartburn may be more likely to have 
acid- related NERD (true NERD), subgroup analyses of the propor-
tions of heartburn- free days during the 4- week treatment period and 
daily proportions of patients without heartburn were performed in 
patients with NERD, who experienced moderate and severe heart-
burn during the screening period (n = 41, n = 42 and n = 39 in tego-
prazan 50 mg, 100 mg and placebo groups, respectively).
Safety was evaluated by TEAEs at weeks 2 and 4, and follow- up 
visits as well as physical examination, electrocardiogram, vital 
signs (blood pressure, heart rate and temperature) and laboratory 
test results (haematology, blood chemistry, blood coagulation 
test and urinalysis). Laboratory data were monitored for clinically 
significant changes from baseline. Adverse drug reactions were 
defined as adverse events for which a causal relationship could 
not be ruled out. All adverse events reported during the study, 
regardless of their relationship with the study drug, were recorded 
in detail in terms of the date of onset, duration (if applicable), seri-
ousness, severity, the required treatment modification, the causal 
relationship with the study medication and the outcome. Adverse 
events, adverse drug reactions and serious adverse events were 
recorded using MedDRA 19.1 and classified by System Organ 
Class and Preferred Term.
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2.4 | Statistical analysis
Based on previous study results,24 assuming 19.9% difference in the 
outcome proportion from placebo group, number of patients with 
this assumption was 86 in each treatment group to observe inter-
group differences in the proportion of patients with complete reso-
lution of major symptoms (heartburn and regurgitation) at week 4 of 
the treatment period with a power of 80% at a significance level of 
0.05. Additionally, the total sample size was 324 subjects with 108 
patients per group considering 20% dropout.
Efficacy assessments were analysed primarily in the full- analysis 
set (FAS). Safety assessments were analysed in the safety set. For 
the primary endpoint, the proportion of patients with complete 
resolution of the major symptoms for the last 7 days of week 4 
(treatment period), according to the RDQ score, was calculated in 
the FAS. Chi- square and Fisher's exact tests were used to compare 
the primary endpoints, the complete resolution rate of heartburn or 
regurgitation, the proportion of heartburn- free days and the daily 
proportion of patients without heartburn between tegoprazan and 
placebo administrations. Hochberg method was used to adjust the 
significance level for multiple comparisons.
Statistical analyses were performed using SAS version 9.3 (SAS 




Out of the 386 patients enrolled in the study, 47 subjects were ineligi-
ble based on the inclusion/exclusion criteria, 13 subjects withdrew the 
consent and two subjects were determined ineligible for other reasons 
by the investigator. A total of 324 eligible patients were randomised 
into the three treatment arms, including tegoprazan 50 mg (n = 108), 
100 mg (n = 108) and placebo (n = 108). Twenty patients (6.2%) did not 
complete the study. One subject, assigned to the placebo arm, with-
drew consent before taking the study drug and was excluded from the 
safety set analysis. Additionally, 19 (5.9%) were discontinued from the 
study due to inclusion/exclusion criteria violation (n = 4, 1.2%) and no 
collection of efficacy data (n = 14, 4.3%) (Figure 2).
The patients' and baseline characteristics are summarised in 
Table 1. No significant differences in baseline characteristics were 
observed between the treatment groups.
3.2 | Efficacy analysis
3.2.1 | Complete resolution rates of major symptoms 
(both heartburn and regurgitation)
The proportion of patients with complete resolution of major symptoms 
(heartburn and regurgitation) for the last 7 days of the treatment (week 
4) were 42.5% (45/106) with tegoprazan 50 mg, 48.9% (48/99) with 
the tegoprazan 100 mg and 24.2% (24/99) with placebo, respectively 
(Table 2). All doses of tegoprazan were superior in terms of completely 
resolving major symptoms compared with the placebo (P = 0.0058 and 
P = 0.0004 for tegoprazan 50 and 100 mg, respectively).
The complete resolution rates of the major symptoms at week 2 
were 16.0% (17/106), 23.2% (23/99) and 10.0% (10/99) in the tego-
prazan 50 mg, tegoprazan 100 mg and placebo groups, respectively. 
However, a statistically significant difference was only observed in 
the tegoprazan 100 mg group (P = 0.0264).
3.2.2 | Complete resolution rates of heartburn
The proportion of patients with complete resolution of heartburn 
for the last 7 days was significantly higher in all tegoprazan groups 
than that in the placebo group at both weeks 2 and 4 (Table 2). The 
complete resolution rates of heartburn were 40.6% (43/106) with te-
goprazan 50 mg, 42.4% (42/99) with tegoprazan 100 mg, and 26.3% 
F I G U R E  2   Proportion of heartburn- 
free days, according to the full- analysis 
set or subgroup analysis of patients, 
who experienced moderate or severe 
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(26/99) with placebo at week 2, respectively. At week 4, the overall 
rates were further increased than those of week 2; 62.3% (66/106) 
with tegoprazan 50 mg, 65.7% (65/99) with tegoprazan 100 mg and 
43.4% (43/99) with placebo, respectively.
3.2.3 | Complete resolution rates of 
regurgitation or dyspepsia
The proportion of patients with complete resolution of regurgitation for 
the last 7 days showed higher trend in all tegoprazan groups than that 
in the placebo group at week 4; 54.7% (58/106) with tegoprazan 50 mg, 
60.6% (60/99) with tegoprazan 100 mg and 48.5% (48/99) with placebo, 
respectively, but the differences were not statistically significant (Table 2).
The proportion of patients with complete resolution of dyspep-
sia for the last 7 days were similar in all groups at week 4; 63.2% 
(67/106) with tegoprazan 50 mg, 66.7% (66/99) with tegoprazan 
100 mg and 64.7% (64/99) with placebo, respectively (Table 2).
3.2.4 | Proportion of heartburn- free days
The proportion of heartburn- free days during the 4- week treatment pe-
riod was 67.6% with tegoprazan 50 mg, 66.5% with tegoprazan 100 mg 
and 56.7% with placebo, respectively (Table 2, Figure 2). The proportions 
of heartburn- free days with both tegoprazan 50 and 100 mg were higher 
to those of the placebo (P = 0.0103 and P = 0.0210, respectively).
3.3 | Subgroup analyses
Subgroup analysis for proportions of heartburn- free days during a 
4- week treatment period and daily proportions of patients without 
heartburn were evaluated in patients with NERD, who experienced 
heartburn with moderate and severe severity during screening period.
The proportions of heartburn- free days during a 4- week treat-
ment period in a subgroup analysis were 67.5% with tegoprazan 
50 mg, 67.3% with tegoprazan 100 mg and 46.7% with placebo, re-
spectively (Figure 2). The proportions of heartburn- free days after 
administering both tegoprazan 50 and 100 mg were higher than 
those of the placebo (P = 0.0030 and P = 0.0029, respectively).
The daily proportions of patients without heartburn in a sub-
group analysis were overall higher in all tegoprazan groups than in 
the placebo group, from day 1 and throughout the 4- week treatment 
period (Figure 3).
3.4 | Safety analysis
A total of 323 patients received at least one dose of the study drug and 
were included in the safety analysis. Neither deaths nor unexpected seri-
ous TEAEs were reported. Most TEAEs (79.6%, 78/98) were mild in se-
verity; meanwhile, severe ones were not detected in any of the groups 
(Table 3). The percentages of patients with more than one TEAE were 
19.4%, 22.2% and 20.6% for the tegoprazan 50 mg, 100 mg and placebo 
groups, respectively (Table 4). Five patients with TEAEs discontinued 
treatments (one, two and two patients in tegoprazan 50 mg, 100 mg and 
placebo groups, respectively). Nausea (2.8%, 3/108) in the tegoprazan 
50 mg group, headache (4.6%, 5/108) in the tegoprazan 100 mg group 
and nasopharyngitis (2.8%, 3/107) in the placebo group were the most fre-
quently reported drug- related TEAEs. A serious TEAE was reported in the 
tegoprazan 100 mg (pyrexia) group and another one in the placebo group 
(haemoptysis), which were considered drug- related. No significant changes 
in vital signs or ECG findings were observed during the study period.
4  | DISCUSSION
This was the first randomised, double- blind, controlled phase 3 study 
that evaluated the effectiveness of tegoprazan, a novel P- CAB, in 
Demographics
Tegoprazan Placebo
50 mg (n = 106) 100 mg (n = 99) (n = 99)
Age (years) 45.4 (12.2) 44.1 (13.3) 45.6 (13.3)
Male (%) 31 (29.3) 37 (37.4) 31 (31.3)
Height (cm) 163.5 (8.8) 164.4 (8.4) 163.9 (8.2)
Weight (kg) 61.3 (10.8) 63.3 (11.8) 62.7 (12.1)
Body mass index (kg/m2) 22.9 (3.2) 23.3 (3.4) 23.2 (3.0)
≥25 and ≤30, n (%) 22 (20.8) 20 (20.2) 27 (27.3)
>30, n (%) 2 (1.9) 4 (4.0) 1 (1.0)
Smoking, n (%) 12 (11.3) 19 (19.2) 11 (11.1)
Alcohol consumption, n (%) 33 (31.1) 39 (39.4) 33 (33.3)
Note: Values are presented as mean (standard deviation) except for gender, smoking, and alcohol 
consumption, which were presented as mean (%).
Abbreviation: n, number of patients.
TA B L E  1   Demographic characteristics 
(full- analysis set)
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324 Korean patients with NERD. Four weeks of treatment with te-
goprazan 50 and 100 mg once daily significantly increased the reso-
lution rate of major symptoms (both heartburn and regurgitation) 
compared with placebo administration.
Tegoprazan 50 and 100 mg also achieved significantly higher 
complete heartburn resolution rates at weeks 2 and 4 and propor-
tion of heartburn- free days during 4- week of treatment period com-
pared with the placebo. The responses for complete resolution rates 
of heartburn observed in this study were comparable with those 
previously obtained with PPIs in patients with NERD.25,26
NERD, characterised by the presence of typical GERD symptoms 
without oesophageal erosion at upper endoscopy, negatively influ-
ences the QoL of patients.6,8 PPIs are currently used as the most 
effective treatment for GERD, but reflux symptoms are not com-
pletely controlled in a significant number of patients with NERD.7 
Additionally, the responses to PPI therapy were higher in patients 
with ERD than those with NERD,12,27,28 which suggested that these 
two disorders might have different underlying pathogeneses.7,13 The 
characteristics and pathophysiology of NERD led to administration 
of higher dose of tegoprazan than the approved ones for treatment 
TA B L E  2   Summary of efficacy results (full- analysis set)
Parameters
Tegoprazan Placebo P- value (vs placebo)
50 mg (n = 106) 100 mg (n = 99) (n = 99) [tegoprazan 50 mg; 100 mg]
Complete resolution of major symptoms (RDQ score)
Week 4, n (%) 45 (42.5) 48 (48.5) 24 (24.2) [P = 0.0058; P = 0.0004]a 
[Difference from placebo, n (%)] [23 (18.3)] [24 (24.3)]
Week 2, n (%) 17 (16.0) 23 (23.2) 10 (10.1) [P = 0.2091; P = 0.0264]a 
[Difference from placebo, n (%)] [7 (5.9)] [13 (13.1)]
Complete resolution of heartburn (RDQ score)
Week 4, n (%) 66 (62.3) 65 (65.7) 43 (43.4) [P = 0.0069; P = 0.0017]a 
[Difference from placebo, n (%)] [20 (18.9)] [22 (22.3)]
Week 2, n (%) 43 (40.6) 42 (42.4) 26 (26.3) [P = 0.0303; P = 0.0166]a 
[Difference from placebo, n (%)] [17 (14.3)] [16 (16.1)]
Complete resolution of regurgitation (RDQ score)
Week 4, n (%) 58 (54.7) 60 (60.6) 48 (48.5) [P = 0.3722; P = 0.1736]a 
[Difference from placebo, n (%)] [10 (6.2)] [12 (12.1)]
Complete resolution of dyspepsia (RDQ score)
Week 4, n (%) 67 (63.2) 66 (66.7) 64 (64.7) [P = 0.8303; P = 0.7647]a 
[Difference from placebo, n (%)] [3 (−1.5)] [2 (2.0)]
Proportion of heartburn- free days, % (SD) 67.6 (29.8) 66.5 (29.1) 56.7 (30.3) [P = 0.0103; P = 0.0210]b 
[Difference from placebo, %] [10.9] [9.8]
Abbreviations: n, number of patients; SD, standard deviation.
aChi- square test, the P- values were adjusted for multiple comparisons (overall familywise type I error of 5%) by the Hochberg procedure.
bUnpaired t test, the P- values were adjusted for multiple comparisons (overall familywise type I error of 5%) by the Hochberg procedure.
F I G U R E  3   Daily proportions of 
patients without heartburn during 
treatment period, who experienced 
moderate or severe heartburn symptom 























































P = 0.0304 P = 0.0143
P = 0.0058
P = 0.0314
Tegoprazan 50 mg (n = 41)
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of ERD in this study. Our data showed that an increased dose of 
tegoprazan was more helpful to patients with NERD if it provided 
a significant relief of the major symptoms, in cases where typical 
GERD symptoms were not achieved with the standard dose.
Differences from placebo for complete resolution rates of heart-
burn in tegoprazan groups (14.3% and 16.2% for tegoprazan 50 and 
100 mg, respectively) were higher than those for the major symptoms, 
both heartburn and regurgitation (5.9% and 13.1%, respectively) at 
week 2, whereas the differences were comparable at week 4. Moreover, 
complete resolution rates of regurgitation were higher in tegoprazan 
groups compared with the response of placebo but those differences 
were not statistically significant, which was consistent with previous 
reports that regurgitation was less responsive to acid suppression than 
heartburn in patients with GERD.29 Interestingly, responses to tego-
prazan 50 and 100 mg were comparable in terms of heartburn but not 
for the complete resolution of major symptoms. Because regurgitation 
was less responsive to acid suppressant, the complete resolution rate 
of the major symptoms at week 2 was not significantly different be-
tween administration of tegoprazan 50 mg and placebo.
Even though several attempts to improve the development of 
P- CAB and thus overcome the major disadvantages of PPIs have 
been made, the evidence of the P- CAB therapeutic potential in the 
treatment of NERD is limited. Recently, two randomised, placebo- 
controlled phase 3 studies reported that vonoprazan was not sig-
nificantly superior to the placebo in achieving the primary efficacy 
outcome (proportion of days without heartburn during the 4- week 
treatment period) in the FAS of patients with NERD.30,31 It is unex-
pected that vonoprazan did not achieve the superiority in the primary 
efficacy outcome for treatment of NERD compared with placebo, 
although it was reported the superior inhibition of gastric acid secre-
tion by P- CAB did not translate into an improved clinical benefit over 
PPI (active comparator) in patients with NERD.32 Yoshikazu et al ex-
plained that the partial response of vonoprazan monotherapy may be 
due to the heterogeneous pathophysiology of NERD.30,31 Additionally, 
Ryota et al and Satoshi et al reported that vonoprazan was effective 
in relieving the gastroesophageal reflux symptoms in patients with 
PPI- resistant NERD.33,34 These studies do not discard the possibility 
that P- CAB could be effectively used in NERD; however, these results 
should be confirmed in larger randomised controlled trials.
Tegoprazan was approved in Korea for the treatment of ERD, 
NERD, gastric ulcer and eradication of Helicobacter pylori35,36 and 
became the first P- CAB clinically available for patients with NERD. 
Because tegoprazan exhibited a rapid acid inhibition and long- 
lasting effect in previous studies,18,19 it is plausible that tegoprazan 
may have a better therapeutic effect in acid- related diseases. This 
study confirmed that tegoprazan was superior to the placebo in 
the achieving the primary efficacy outcome and heartburn- related 
secondary efficacy outcomes (complete resolution rates of heart-
burn for the last 7 days of weeks 2 and 4, and proportion of days 
without heartburn during the 4- week treatment period) in patients 
with NERD. Although patients who participated in this study had 
milder heartburn symptoms than those in the vonoprazan studies, 
subgroup analyses of the proportions of heartburn- free days and 
the daily proportions of patients without heartburn revealed that 
tegoprazan provided rapid and sustained heartburn relief to patients 
with NERD, who experienced heartburn symptom with moderate 
and higher severity in the screening period, from day 1 and through-
out the treatment period (Figures 2 and 3). This rapid and sustained 
TEAE
Tegoprazan
Placebo50 mg 100 mg
(n = 108) (n = 108) (n = 107)
n (%) [F] n (%) [F] n (%) [F]
TEAE 21 (19.4) [29] 24 (22.2) [32] 22 (20.6) [37]
Related 13 (12.0) [19] 12 (11.1) [14] 13 (12.2) [23]
Not related 8 (7.4) [10] 12 (11.1) [14] 10 (9.4) [14]
Mild 18 (16.7) [21] 23 (21.3) [28] 20 (18.7) [29]
Moderate 4 (3.7) [8] 3 (2.8) [4] 6 (5.6) [8]
Severe 0 (0.0) [0] 0 (0.0) [0] 0 (0.0) [0]
Leading to 
discontinuation
0 (0.0) [0] 2 (1.9) [2] 1 (1.985) [2]
SAE 0 (0.0) [0] 1 (0.9) [1] 1 (0.9) [1]
Related 0 (0.0) [0] 1 (0.9) [1] 1 (0.9) [1]
Not related 0 (0.0) [0] 0 (0.0) [0] 0 (0.0) [0]
Leading to 
discontinuation
0 (0.0) [0] 1 (0.9) [1] 0 (0.0) [0]
Deaths 0 (0.0) [0] 0 (0.0) [0] 0 (0.0) [0]
Abbreviations: [F], Frequency of TEAEs; SAEs, serious adverse events; TEAEs, treatment- emergent 
adverse events.
TA B L E  3   Summary of safety outcomes 
(safety analysis set)
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symptom relief supports that tegoprazan may provide on- demand 
therapeutic option to patients with NERD.
According to the safety analysis, no significant differences in the 
incidence of TEAEs between tegoprazan and placebo groups were 
noted (19.4%, 22.2% and 20.6% for tegoprazan 50 mg, 100 mg and 
placebo, respectively). Moreover, no significant drug- related TEAEs 
were reported throughout the study, confirming a favourable safety 
profile for the oral administration of tegoprazan.
This study has several limitations. First, it is difficult to generalise 
the study results for non- Korean populations. The design of this study 
was not active- controlled. The beneficial features of tegoprazan, such 
as fast onset, no food effect, nocturnal acid breakthrough control 
and less inter- individual variation due to different PPIs metabolism 
pathways, were not reflected in the design of this study. There was 
no information on disposition of patients infected with H. pylori infec-
tion in this randomised study although it is still controversy if status 
of H. pylori infection affects symptom outcomes of PPIs in patients 
with NERD. In addition, due to the multifactorial pathophysiology of 
NERD and no intra- oesophageal pH monitoring before enrolment, the 
patient population recruited in this study may have included patients 
with true NERD, oesophageal hypersensitivity, functional heartburn 
and functional dyspepsia, which could affect the outcome responses.
In conclusion, oral administration of 50 and 100 mg of the novel 
P- CAB tegoprazan, once daily for 4 weeks, resulted in a statistically 
superior efficacy over the placebo in terms of complete resolution 
of RDQ- based major symptoms in patients with NERD. Tegoprazan 
also significantly increased the complete heartburn relief rates at 
both weeks 2 and 4 and the percentage of heartburn- free days, com-
pared with those observed in the placebo group. Tegoprazan provided 
effective and sustained symptom relief to NERD patients, constitut-
ing an effective therapeutic option for the treatment of NERD.
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TEAE
Tegoprazan
Placebo50 mg 100 mg
(n = 108) (n = 108) (n = 107)
n (%) [F] n (%) [F] n (%) [F]
Most frequently reported TEAEs by system organ class and preferred terma 
Nervous system disorders 2 (1.9) [2] 6 (5.6) [6] 3 (2.8) [5]
Headache 2 (1.9) [2] 4 (3.7) [4] 5 (4.7) [5]
Infections and infestations 4 (3.7) [4] 5 (4.6) [5] 6 (5.6) [6]
Nasopharyngitis 3 (2.8) [3] 4 (3.7) [4] 5 (4.7) [5]
Most frequently reported drug- related TEAEs by system organ class and preferred termb 
Gastrointestinal disorders 8 (7.4) [13] 3 (2.8) [3] 7 (6.5) [8]
Nausea 3 (2.8) [5] 1 (0.9) [1] 2 (1.9) [2]
Infections and infestations 1 (0.9) [1] 2 (1.9) [2] 3 (2.8) [3]
Nasopharyngitis 1 (0.9) [1] 2 (1.9) [2] 3 (2.8) [3]
Nervous system disorders 1 (0.9) [1] 5 (4.6) [5] 2 (1.9) [3]
Headache 1 (0.9) [1] 5 (4.6) [5] 2 (1.9) [3]
Abbreviations: [F], Frequency of TEAEs; SAEs, serious adverse events.
a≥4%.
b≥2%.
TA B L E  4   Summary of treatment- 
emergent adverse events (TEAEs) and 
drug- related TEAEs (safety analysis set)
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